1-3 of 3
Oumar Sy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004

George Somlo, Francesco Atzori, Lewis C. Strauss, William J. Geese, Jennifer M. Specht, William J. Gradishar, Alissa Rybicki, Oumar Sy, Linda T. Vahdat, Javier Cortes
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1884–1893.
https://doi.org/10.1158/1078-0432.CCR-12-0652
Published: 02 April 2013
View article titled, Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004
Open the PDF for Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 in another window
Includes: Supplementary data
Journal Articles

Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

Richard S. Finn, Carmelo Bengala, Nuhad Ibrahim, Henri Roché, Joseph Sparano, Lewis C. Strauss, Justin Fairchild, Oumar Sy, Lori J. Goldstein
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (21): 6905–6913.
https://doi.org/10.1158/1078-0432.CCR-11-0288
Published: 31 October 2011
View article titled, Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
Open the PDF for Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study in another window
Journal Articles

A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer

Erica L. Mayer, Jean-Francois Baurain, Joseph Sparano, Lewis Strauss, Mario Campone, Pierre Fumoleau, Hope Rugo, Ahmad Awada, Oumar Sy, Antonio Llombart-Cussac
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (21): 6897–6904.
https://doi.org/10.1158/1078-0432.CCR-11-0070
Published: 31 October 2011
View article titled, A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer
Open the PDF for A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer in another window